Altimmune Plans Phase 3 MASH Trial as Pemvidutide Gains Breakthrough Status
Event summary
- Altimmune plans to initiate a Phase 3 MASH trial for pemvidutide in 2026, following FDA Breakthrough Therapy Designation.
- Pemvidutide showed statistically significant improvements in key non-invasive markers of fibrosis and inflammation in the IMPACT Phase 2b trial.
- Altimmune raised $75 million in a registered direct offering in January 2026, bringing total cash and investments to $340 million as of February 28, 2026.
- Topline data from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) is expected in the third quarter of 2026.
The big picture
Altimmune's strategic focus on pemvidutide positions it to address critical unmet needs in serious liver diseases, particularly MASH. The company's recent financial strengthening and regulatory milestones underscore its commitment to advancing the compound through Phase 3 development. The biopharmaceutical industry is increasingly focused on innovative therapies for liver diseases, and Altimmune's progress could position it as a key player in this space.
What we're watching
- Regulatory Strategy
- How the FDA Breakthrough Therapy Designation will accelerate pemvidutide's path to market for MASH.
- Clinical Execution
- Whether Altimmune can successfully initiate and complete the Phase 3 MASH trial as planned in 2026.
- Financial Runway
- The pace at which Altimmune will need to secure additional funding to support its clinical programs beyond 2026.
Related topics